J Gynecol Oncol.  2015 Oct;26(4):293-302. 10.3802/jgo.2015.26.4.293.

Synchronous and metachronous malignancy in endometrial cancer patients treated in a tertiary care center of Thailand

• Tangjitgamol S
• Khunnarong J
• Srijaipracharoen S

• KMID: 2345920
• DOI: http://doi.org/10.3802/jgo.2015.26.4.293

Abstract

OBJECTIVE
To evaluate the prevalence and features of non-endometrial cancers in Thai endometrial cancer (EC) patients.
METHODS
EC patients treated in our institution were identified and the following data were collected: age, EC stage, histopathology, adjuvant therapy, other cancers, living status, and cause of death.
RESULTS
The mean age of the 344 patients was 56.8+/-10.8 years. Fifty (14.5%) had other synchronous and metachronous cancers. Mean ages of the patients with or without other cancers were not significantly different, 55.7+/-10.04 years versus 57.1+/-11.0 years, respectively (p=0.358). History of any cancer in the family and tumor in the lower uterine segment were more frequent among the patients with other cancers (6.0% vs. 1.7%, p=0.095; 12.0% vs. 1.0%, p<0.001; respectively). Six patients had > or =2 other cancers. Ovarian, breast, and colon were the three most common other cancers. After a median follow-up of 57.1 months, 18.3% of patients had died: 30.0% of patients with other cancers and 16.3% of those without other cancers. The corresponding EC deaths were 14.0% and 11.2%. The 5-year overall survival was significantly lower in patients who had other cancers: 79.3% (95% confidence interval [CI], 68.3 to 90.3) vs. 86.0% (95% CI, 81.7 to 90.3) than in those without (p=0.023). However, the corresponding disease-specific survival was not significantly different: 85.1% (95% CI, 75.5 to 94.7) compared with 89.0% (95% CI, 85.1 to 92.9), respectively (p=0.514).
CONCLUSION
Thai EC patients had a high incidence of other cancers. Overall survival of EC patients who had other cancers was worse than those without, while disease-specific survival was not significantly different.

Keyword

Endometrial Cancer; Non-endometrial Cancers; Metachronous, Synchronous

MeSH Terms

Breast Neoplasms/mortality/pathology/therapy
Chemotherapy, Adjuvant/methods
Colonic Neoplasms/mortality/pathology/therapy
Disease-Free Survival
Endometrial Neoplasms/mortality/*pathology/therapy
Female
Humans
Kaplan-Meier Estimate
Middle Aged
Neoplasm Recurrence, Local/mortality
Neoplasms, Multiple Primary/mortality/*pathology/therapy
Neoplasms, Second Primary/mortality/*pathology/therapy
Radiotherapy, Adjuvant/methods
Tertiary Care Centers/statistics & numerical data
Thailand/epidemiology

Reference

1. Ferlay J, Soerjomataram I, Ervik M, Forman D, Bray F, Dikshit R, et al. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 [Internet]. Lyon: International Agency for Research on Cancer;c2015. cited 2014 Jan 25. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.

2. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983; 15:10–17.

3. Crosbie EJ, Zwahlen M, Kitchener HC, Egger M, Renehan AG. Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2010; 19:3119–3130.

4. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012; 35:2402–2411.

5. Dossus L, Lukanova A, Rinaldi S, Allen N, Cust AE, Becker S, et al. Hormonal, metabolic, and inflammatory profiles and endometrial cancer risk within the EPIC cohort: a factor analysis. Am J Epidemiol. 2013; 177:787–799.

6. Lynch HT, Lanspa S, Smyrk T, Boman B, Watson P, Lynch J. Hereditary nonpolyposis colorectal cancer (Lynch syndromes I & II): genetics, pathology, natural history, and cancer control, Part I. Cancer Genet Cytogenet. 1991; 53:143–160.

7. Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control. 2009; 16:14–22.

8. Gruber SB, Thompson WD. Cancer and Steroid Hormone Study Group. A population-based study of endometrial cancer and familial risk in younger women. Cancer Epidemiol Biomarkers Prev. 1996; 5:411–417.

9. Olson JE, Sellers TA, Anderson KE, Folsom AR. Does a family history of cancer increase the risk for postmenopausal endometrial carcinoma? A prospective cohort study and a nested case-control family study of older women. Cancer. 1999; 85:2444–2449.

10. Boice JD Jr, Engholm G, Kleinerman RA, Blettner M, Stovall M, Lisco H, et al. Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res. 1988; 116:3–55.

11. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999; 81:214–218.

12. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999; 116:1453–1456.

13. Watson P, Vasen HF, Mecklin JP, Bernstein I, Aarnio M, Jarvinen HJ, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer. 2008; 123:444–449.

14. Tangjitgamol S, Khunnarong J, Srijaipracharoen S. Medical morbidities in endometrial cancer patients. Int J Gynecol Cancer. 2014; 24:1623–1627.

15. Young RH, Clement PB. Pathology of endometrial carcinoma. In : Fuller AF, Seiden MV, Young RH, editors. American Cancer Society atlas of clinical oncology: uterine cancer. London: BC Decker Inc.;2004. p. 52–77.

16. Yoo HJ, Lim MC, Son Y, Seo SS, Kang S, Kim SH, et al. Survival outcome in endometrial cancer patients according to hereditary predisposition. Taiwan J Obstet Gynecol. 2015; 54:24–28.

17. Simpson ER, Brown KA. Minireview: obesity and breast cancer: a tale of inflammation and dysregulated metabolism. Mol Endocrinol. 2013; 27:715–725.

18. Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med. 2014; 160:255–266.

19. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994; 86:527–537.

20. United Nations Scientific Committee on the Effects of Atomic Radiation. UNSCEAR 2000 report. Volume II. Sources and effects of ionizing radiation. Annex F: DNA repair and mutagenesis [Internet]. United Nations Scientific Committee on the Effects of Atomic Radiation;2013. cited 2014 Sep 25. Available from: http://www.unscear.org/docs/reports/annexf.pdf.

21. Parazzini F, La Vecchia C, Moroni S, Chatenoud L, Ricci E. Family history and the risk of endometrial cancer. Int J Cancer. 1994; 59:460–462.

22. Vasen HF, Watson P, Mecklin JP, Jass JR, Green JS, Nomizu T, et al. The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer. Anticancer Res. 1994; 14:1675–1678.

23. Westin SN, Lacour RA, Urbauer DL, Luthra R, Bodurka DC, Lu KH, et al. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol. 2008; 26:5965–5971.

24. Olsen H, Seersholm N, Boice JD Jr, Kruger Kjaer S, Fraumeni JF Jr. Cancer risk in close relatives of women with early-onset breast cancer: a population-based incidence study. Br J Cancer. 1999; 79:673–679.

25. Evans-Metcalf ER, Brooks SE, Reale FR, Baker SP. Profile of women 45 years of age and younger with endometrial cancer. Obstet Gynecol. 1998; 91:349–354.

26. Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005; 105:575–580.

27. Walsh C, Holschneider C, Hoang Y, Tieu K, Karlan B, Cass I. Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol. 2005; 106:693–699.

28. Manchana T, Khemapech N. Endometrial adenocarcinoma in young Thai women. Asian Pac J Cancer Prev. 2008; 9:283–286.

29. Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Tanvanich S, Khunnarong J, Thavaramara T, et al. Clinicopathological features including hormonal receptor expression and survival in young endometrial cancer patients: a case control study. Asian Pac J Cancer Prev. 2010; 11:1487–1492.

30. Freedman DM, Curtis RE, Travis LB, Fraumeni JF. New malignancies following cancer of the uterine corpus and ovary. In : Curtis RE, Freedman DM, Ron E, Ries LA, Hacker DG, Edwards BK, editors. New malignancies among cancer survivors: SEER cancer registries, 1973-2000. Bethesda, MD: National Cancer Institute;2006. p. 231–235.

31. Lee KD, Chen CY, Huang HJ, Wang TY, Teng D, Huang SH, et al. Increased risk of second primary malignancies following uterine cancer: a population-based study in Taiwan over a 30-year period. BMC Cancer. 2015; 15:393.

32. Moline J, Mahdi H, Yang B, Biscotti C, Roma AA, Heald B, et al. Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center. Gynecol Oncol. 2013; 130:121–126.

33. Yoo HJ, Joo J, Seo SS, Kang S, Yoo CW, Park SY, et al. Correlation between body mass index and prevalence of hereditary nonpolyposis colorectal cancer in Korean patients with endometrial cancer. Int J Gynecol Cancer. 2012; 22:267–272.

34. Lim MC, Seo SS, Kang S, Seong MW, Lee BY, Park SY. Hereditary non-polyposis colorectal cancer/Lynch syndrome in Korean patients with endometrial cancer. Jpn J Clin Oncol. 2010; 40:1121–1127.